Figure 2 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors

Q: What type of study is this?

This is a Quantitative Study study.

John D. Powderly; Martina Imbimbo; Antoîne Italiano; Patricia Martín-Romano; Meredith McKean; Teresa Macarulla; Eduardo Castañón Álvarez; Benedito A. Carneiro; Raymond Mager; Vicky Barnhart; Steven Eck; Elina Murtomaki; Arsène‐Bienvenu Loembé; Yun He; Zachary A. Cooper; Eric Tu; Chunling Fan; Agnes Boyer Chamard; Carine Paturel; Paula G. Fraenkel; Antoine Hollebecque

doi:10.1158/2767-9764.30177727

Key Points

Serum concentrations of iph5201 were measured across different dose cohorts, and data showed variability with treatment.
Geometric mean serum concentrations were calculated using pharmacokinetic analysis, providing mean values and standard deviations.
Patients included in the study had to receive at least one dose of treatment and provide quantifiable post-treatment samples.
The pharmacokinetic analysis set was defined to accurately assess the impacts of iph5201 and durvalumab on tumor progression.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Analysis shows serum concentration of iph5201 and durvalumab in advanced solid tumors, highlighting dosing impacts.

Abstract

Mean (± SD) serum concentration of IPH5201 across dose cohorts and treatment. Data are shown based on the PK analysis set, defined as patients who received ≥1 dose of IPH5201 or durvalumab (durva) and provided ≥1 quantifiable posttreatment sample. Vertical lines represent the geometric ± SD. Geometric mean SD was calculated as the exponential [mean (log (PK concentration)) ± SD (log (PK concentration))]. PK, pharmacokinetic; SD, standard deviation.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Powderly et al. (2025) studied this question.

synapsesocial.com/papers/68d4725631b076d99fa6b12f https://doi.org/10.1158/2767-9764.30177727

View Full Paper

Ask AI

Bookmark

Share

Figure 2 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Figure 2 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading